Research Use Only - Not for human consumption. 18+ only.
FDA ApprovedCognitive EnhancementIntravenousIntramuscular

Cerebrolysin

Also known as: FPF-1070, Brain-derived peptides

Cerebrolysin is a mixture of neurotrophic peptides derived from pig brain. It mimics the effects of neurotrophic factors and shows promise for neurodegenerative diseases and traumatic brain injury.

Research Status

FDA Approved

Approved in some countries, research compound in others

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Neuroprotective and neurotrophic effects
May improve cognitive function
Supports stroke recovery
Potential for Alzheimer's and dementia
Enhances neuroplasticity
Improves TBI recovery

Side Effects

Injection site pain or discomfort
CommonMild

Occurs at IM or IV injection sites. Typically resolves within 24 hours. Reduce by allowing solution to warm to room temperature before injection and rotating injection sites. Apply ice if needed.

Mild headache
UncommonMild

May occur during the first few days of treatment. Usually self-resolving. Ensure adequate hydration and rest.

Dizziness or lightheadedness
UncommonMild

More common with IV administration. Sit or lie down if symptoms occur. Typically resolves within minutes to hours.

Nausea
UncommonMild

May occur, especially with IV administration. Take with food if tolerated. Symptoms usually resolve within 24 hours.

Fever or chills
RareMild

Rare; may indicate a reaction to the porcine-derived material. Monitor temperature. If fever persists beyond 24 hours, seek medical evaluation.

Allergic reaction (rash, urticaria, angioedema)
RareSerious

Cerebrolysin is derived from porcine brain tissue; individuals with porcine protein allergies are at higher risk. Symptoms may include itching, hives, facial swelling, or difficulty breathing. Seek immediate medical attention if any signs of anaphylaxis occur. Have antihistamines and epinephrine available.

Phlebitis or thrombophlebitis (IV administration)
UncommonModerate

Inflammation of the vein at the IV site. Risk increases with prolonged IV infusions or repeated use of the same vein. Rotate IV sites and use proper aseptic technique. Symptoms include redness, warmth, swelling, or pain along the vein. Seek medical evaluation if symptoms develop.

Muscle pain or myalgia
UncommonMild

May occur at or near IM injection sites. Usually resolves within 48 hours. Apply heat or take over-the-counter analgesics if needed.

Insomnia or sleep disturbance
UncommonMild

Cerebrolysin may have mild stimulant-like effects on the central nervous system. Avoid injections late in the day. Symptoms typically resolve after treatment discontinuation.

Agitation or anxiety
RareMild

Rare; may occur in sensitive individuals. Usually mild and self-resolving. Discontinue if symptoms are bothersome and consult a healthcare provider.

Seizures
RareSerious

Very rare; reported in isolated cases, particularly in individuals with a history of seizure disorders. Cerebrolysin should be used with caution in patients with epilepsy. Seek immediate medical attention if seizure activity occurs.

Dosing Reference

ParameterValue
Dose range5-30 mL
FrequencyDaily for 10-30 days
TimingMorning
RouteIntravenous, Intramuscular

IV or IM administration. Cycles of 10-30 days followed by breaks.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Half-lifeApproximately 6-8 hours (estimated from clinical pharmacokinetics; exact half-life varies by individual peptide components)

Cerebrolysin is a standardised mixture of neuropeptides and amino acids derived from porcine brain tissue that mimics the effects of endogenous neurotrophic factors, particularly nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). It crosses the blood-brain barrier and promotes neuronal survival, differentiation, and synaptic plasticity through activation of neurotrophic signalling pathways. The peptide mixture enhances cellular energy metabolism and reduces neuroinflammation, making it a candidate for treating neurodegenerative conditions and traumatic brain injury.

Neurotrophic Factor Signalling (NGF/BDNF-like)

Cerebrolysin components bind to and activate tropomyosin receptor kinase (Trk) receptors and p75 neurotrophin receptors, triggering intracellular cascades that promote neuronal survival and axonal growth.

Neuroprotection and Anti-apoptosis

The peptide mixture activates phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways, which suppress pro-apoptotic signals and enhance neuronal cell survival.

Synaptic Plasticity and Neurogenesis

Cerebrolysin enhances long-term potentiation (LTP) and promotes neurogenesis in the hippocampus and other brain regions, supporting cognitive recovery and learning.

Anti-inflammatory and Antioxidant Effects

The peptide mixture reduces microglial activation and pro-inflammatory cytokine production (TNF-α, IL-6), while enhancing antioxidant enzyme expression to protect against oxidative stress.

Cellular Energy Metabolism

Cerebrolysin improves mitochondrial function and ATP production in neurons, supporting recovery from metabolic stress induced by ischaemia or trauma.

  • Cerebrolysin is a complex mixture of 15+ neuropeptides and free amino acids, not a single defined peptide — this makes standardisation and mechanism studies challenging
  • The peptide mixture has been shown in clinical trials to improve cognitive function and motor recovery in stroke, traumatic brain injury, and age-related cognitive decline
  • Cerebrolysin crosses the blood-brain barrier via receptor-mediated endocytosis and direct peptide transport mechanisms
  • The neuroprotective effects are dose-dependent and require sustained administration over 10-30 days for optimal clinical benefit
  • Animal studies demonstrate enhanced neuroplasticity and reduced neuroinflammation; human clinical evidence is moderate but supports use in acute and chronic neurological conditions

Track your Cerebrolysin research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Cerebrolysin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.